CAJ | 학술논문

程序性死亡受体（PD）-1/PD-L1信号通路作为T细胞免疫反应的协同刺激信号通路，在适应性免疫中发挥着重要的作用。 PD-1是一种主要表达在T细胞上的共受体，与其配体（PD-L1，PD-L2）结合能够抑制T细胞的活化，使机体免受自身免疫系统的攻击。除了调节并维持自身免疫耐受，在肿瘤细胞中PD-L1的表达上调，而在被病毒感染的T细胞中PD-1的表达也会上调，PD-1/PD-L1参与了肿瘤细胞及传染性病原体的免疫逃逸，因此阻断PD-1/PD-L1信号通路已成为肿瘤和慢性传染病研究的热点。目前，已经有多个抗PD-1、PD-L1单克隆抗体被FDA批准进入临床试验，用于癌症的治疗，疗效显著。
정서성사망수체（PD）-1/PD-L1신호통로작위T세포면역반응적협동자격신호통로，재괄응성면역중발휘착중요적작용。 PD-1시일충주요표체재T세포상적공수체，여기배체（PD-L1，PD-L2）결합능구억제T세포적활화，사궤체면수자신면역계통적공격。제료조절병유지자신면역내수，재종류세포중PD-L1적표체상조，이재피병독감염적T세포중PD-1적표체야회상조，PD-1/PD-L1삼여료종류세포급전염성병원체적면역도일，인차조단PD-1/PD-L1신호통로이성위종류화만성전염병연구적열점。목전，이경유다개항PD-1、PD-L1단극륭항체피FDA비준진입림상시험，용우암증적치료，료효현저。
PD-1/PD-L1 signaling pathway as a T cell immune response co-stimulatory signaling pathway plays an important role in adaptive immunity. PD-1 is a major co-receptor expressing on T cells, binding with its ligands(PD-L1 and PD-L2), PD-1 can inhibit T cell activation and protect the body against the attacks from its own immune system. In addition to adjusting and maintaining autoimmune tolerance, in tumor cells PD-L1 expression is up-regulated, while in the virus-infected T cells PD-L1 expression is also upregulated. PD-1 / PD-L1 are involved in the tumor and infectious pathogen immune evasion, thus blocking the PD-1 / PD-L1 signaling pathway has become a hot research of cancer and chronic diseases. Currently, there are several anti-PD-1 or PD-L1 monoclonal antibodies approved by the FDA to enter clinical studies, which have shown significant anti-cancer effect.